- Home
- ARHS vs TVTX Comparison
ARHS vs TVTX Comparison
Compare ARHS & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- TVTX
- Stock Information
- Founded
- ARHS 1986
- TVTX 2008
- Country
- ARHS United States
- TVTX United States
- Employees
- ARHS N/A
- TVTX N/A
- Industry
- ARHS Other Specialty Stores
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ARHS Consumer Discretionary
- TVTX Health Care
- Exchange
- ARHS Nasdaq
- TVTX Nasdaq
- Market Cap
- ARHS 1.2B
- TVTX 1.4B
- IPO Year
- ARHS 2021
- TVTX N/A
- Fundamental
- Price
- ARHS $8.51
- TVTX $14.31
- Analyst Decision
- ARHS Buy
- TVTX Strong Buy
- Analyst Count
- ARHS 14
- TVTX 15
- Target Price
- ARHS $11.08
- TVTX $33.57
- AVG Volume (30 Days)
- ARHS 1.3M
- TVTX 1.6M
- Earning Date
- ARHS 08-07-2025
- TVTX 07-31-2025
- Dividend Yield
- ARHS N/A
- TVTX N/A
- EPS Growth
- ARHS N/A
- TVTX N/A
- EPS
- ARHS 0.41
- TVTX N/A
- Revenue
- ARHS $1,287,317,000.00
- TVTX $273,533,000.00
- Revenue This Year
- ARHS $7.07
- TVTX $73.84
- Revenue Next Year
- ARHS $7.64
- TVTX $46.72
- P/E Ratio
- ARHS $21.33
- TVTX N/A
- Revenue Growth
- ARHS 0.71
- TVTX 75.65
- 52 Week Low
- ARHS $6.61
- TVTX $6.80
- 52 Week High
- ARHS $19.03
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- ARHS 47.87
- TVTX 38.47
- Support Level
- ARHS $8.31
- TVTX $13.88
- Resistance Level
- ARHS $8.85
- TVTX $15.04
- Average True Range (ATR)
- ARHS 0.40
- TVTX 0.69
- MACD
- ARHS -0.03
- TVTX 0.02
- Stochastic Oscillator
- ARHS 23.81
- TVTX 24.43
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.